WPG Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

WPG Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.88K	Buy	148 +11	+8%	+$528	﹤0.01%	888
2026 Q1	$7.08K	Buy	137 +6	+5%	+$306	0.01%	785
2025 Q4	$6.51K	Buy	131 +1	+0.8%	+$49	﹤0.01%	827
2025 Q3	$6.21K	Buy	130 +1	+0.8%	+$40	﹤0.01%	835
2025 Q2	$4.07K	Buy	129 +118	+1,073%	+$3.78K	﹤0.01%	943
2025 Q1	$360	Sell	11 -89	-89%	-$3.15K	﹤0.01%	1377
2024 Q4	$3.62K	Buy	+100	New	+$3.52K	﹤0.01%	916

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

WPG Advisers's SUPN Position: Q2 2026 in Review

WPG Advisers increased its Supernus Pharmaceuticals (SUPN) stake by 8% in Q2 2026, buying an estimated $528 and bringing the position to 148 shares worth $6.88K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

WPG Advisers first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.08K in Q1 2026. 131 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

WPG Advisers held 148 shares of Supernus Pharmaceuticals worth $6.88K as of Q2 2026.
WPG Advisers bought 11 Supernus Pharmaceuticals shares in Q2 2026, an estimated $528.
Supernus Pharmaceuticals made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #888 holding.
WPG Advisers first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
WPG Advisers's Supernus Pharmaceuticals position peaked at $7.08K in Q1 2026.
131 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.